Introduction: Brain metastases (BM) are a common and lethal complication of non-small cell
lung cancer (NSCLC) with up to 40% experiencing this complication. The use of erlotinib, a …

Median survival of patients with brain metastases from nonsmall cell lung cancer (NSCLC) is
poor and more effective treatments are urgently needed. We have evaluated the efficacy of …

Background This phase II, open-label study evaluated the efficacy and safety of erlotinib as
second-line therapy in non-small-cell lung cancer (NSCLC) patients with brain metastases …

Background The standard therapy for brain metastasis (BM) in non-small cell lung cancer
(NSCLC) is radiation therapy (RT), although it is associated with complications such as …

Purpose Brain metastasis (BM) is a leading cause of death from non–small-cell lung cancer
(NSCLC). Reasoning that activation of the epidermal growth factor receptor (EGFR) …

Background: Brain metastases commonly occur in non–small cell lung cancer (NSCLC), and
patient prognosis is poor. Erlotinib, a specific inhibitor of epidermal growth factor receptor …

2031 Background: Brain metastasis is a leading cause of death from non-small cell lung
cancer (NSCLC). Because some patients with NSCLC have mutations in the epidermal …

Brain metastases are a common occurrence and a major cause of mortality in non-small-cell
lung cancer, with few systemic treatment options. Although targeting epidermal growth factor …

Survival and treatment options are limited for patients with brain metastases arising from non-
small cell lung cancer (NSCLC). We evaluated erlotinib and gefitinib as salvage treatments …

The incidence of brain metastasis (BM) is high in patients with non-small-cell lung cancer.
Available standard therapeutic options, such as whole-brain radiation therapy and systemic …